Dr. Neil A. Ettinger, MD

Dr. Ettinger practices at St. Luke's Hospital in Chesterfield, Missouri, part of St. Luke's Episcopal-Presbyterian Hospital.

Dr. Ettinger's NPI, 1619086451, was assigned on August 29, 2006. Dr. Ettinger graduated from Washington University School of Medicine in 1983. Dr. Ettinger holds Missouri license R8E82.

Dr. Ettinger's primary practice is St. Luke's Hospital, at 232 S Woods Mill Rd, Chesterfield, MO 63017 in St. Louis County. The practice phone is (314) 434-1500.

Dr. Ettinger's primary practice is St. Luke's Hospital in Chesterfield, Missouri, part of St. Luke's Episcopal-Presbyterian Hospital. Dr. Ettinger is also affiliated with Barnes-Jewish Hospital. The medical group on file is St. Luke's Medical Group. Dmand AI also links Dr. Ettinger to 1 more hospital, 2 group practices and clinics, 1 breast imaging center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ettinger practices, 6 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Ettinger's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Ettinger is licensed in Missouri.

CMS data shows 3,734 Medicare services from Dr. Ettinger across 18 procedure codes in 2024, for 1,114 Medicare patients. Medicare paid $237,679 for them.

CMS counts 1,114 Medicare patients who saw Dr. Ettinger in 2024. The largest group is 75 to 84, with 524 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 1.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ettinger's median patient age at 73, with 47% women.

In 2024, Dr. Ettinger wrote 5,312 Medicare Part D claims for 754 patients. 53% of them were for generic drugs. CMS names the drug for 5,051 of them, across 51 drugs with 11 or more claims each, at $5,068,119 in total drug cost. In 2023, CMS named 4,222 claims across 47 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Ettinger for performance year 2024, reported through an alternative payment model (APM). Dr. Ettinger accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ettinger as offering telehealth.

Dmand AI links 3 papers to Dr. Ettinger in 2020. 2020 was the busiest year, with 2. Dr. Ettinger's most frequent co-authors are Kevin Robert Flaherty, MD, Marilyn K. Glassberg, MD and Lisa H. Lancaster, MD.

Dmand AI links Dr. Ettinger to 7 clinical trials, 4 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Hypertension, Pulmonary, Idiopathic Pulmonary Fibrosis and Pulmonary Fibrosis. United Therapeutics sponsors the most, 3. Open Payments lists research payments to Dr. Ettinger that name 1 trial.

CMS Open Payments shows 1,451 general payments to Dr. Ettinger from 64 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 70% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $114,935. It also lists 14 research payments totaling $2,553 from 2017 to 2019, naming 1 clinical trial.

Dr. Ettinger graduated from Washington University School of Medicine in 1983.